5 Shocking Reasons the “War On Cancer” May Finally Be Over!
Ongoing War Against Cancer...
Patented, proprietary cancer breakthrough from GT Biopharma, Inc. (GTBP) could help millions win their fight against cancer ...
GT Biopharma has pioneered a new approach to cancer treatment that stimulates the body’s Natural Killer cells to locate and destroy cancer cells without the side effects of chemotherapy and radiation, or the ruinous cost and limitations of recently-developed immunotherapies.
And this small biotech has more than just a hint of a cure. Its remarkable new, targeted therapy enlists the body’s own immune system to seek out and destroy cancer cells, while leaving healthy cells completely untouched.
Your immune system is smart. When it’s attacked by a foreign invader like cancer, it creates white blood cells like T-cells and NK (Natural Killer) cells to fight it. But cancer is smart too. It sends false signals to your immune system, tricking it into not attacking it.
One of the biggest challenges with treating cancer is its frightening ability to trick your immune system into ignoring it. With GT Biopharma’s new therapy, the immune system is able to see past its false signals, locate cancerous cells and wipe them out.
GT Biopharma is on the verge of a disruptive, potentially life-saving advance in cancer treatment – with significant advantages over the older CAR-T therapy technology:
- It requires no surgery or toxic anti-viral drugs ...
- It can be done locally, with no need to travel to a specialized clinic ...
- It’s projected to cost as low as $30,000 per patient – virtually guaranteeing rapid adoption once approved ...
- It targets a variety of both liquid and solid tumors (nearly 100% of the market) and promises to wipe out cancer for good,
with no recurrence...
- Plus, it’s designed to be an “off the shelf” solution with easily adjusted dosing.
GT Biopharma (GTBP) has full patent and license to this new therapy...guaranteeing the company a deadlock on this proprietary, cancer-fighting technology for years to come.
I recently recommended GT Biopharma, Inc. (GTBP) to my Strategic Investment subscribers.
And I shared my projections for the company – shown on the chart below – based on my extensive research over the past several months:
The end of cancer could become a reality sooner than anyone expected.
For decades, cancer patients have been forced to choose between some combination of surgery, chemotherapy or radiation.
But now, an elite team of medical researchers, scientists and oncologists at the world-renowned University of Minnesota Cancer Center – led by Dr. Jeffery Miller, one of the world’s top 5 cancer researchers – has cracked the code.
The remarkable promise of this new treatment could bring healthy profits to investors who stake their claim now while this company is still under Wall Street’s radar.
For the past 30 years, I’ve helped my Strategic Investment subscribers build wealth by providing accurate “big picture” forecasts and discovering hidden profit opportunities before Wall Street catches on.
I correctly predicted the market collapses of 1999 and 2007 – and helped steer investors to safety. And I’ve helped investors generate outsized returns by investing in disruptive investments before they exploded in value.
And now I’m recommending GT Biopharma (GTBP) to my Strategic Investment subscribers as a “Strong Buy” for its high upside potential.